Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04NPP
|
|||
| Former ID |
DNCL001638
|
|||
| Drug Name |
SLX-2101
|
|||
| Indication | Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4] | Discontinued in Phase 2 | [1] | |
| Hypertension [ICD-11: BA00-BA04] | Discontinued in Phase 2 | [1] | ||
| Raynaud disease [ICD-11: BD42.0; ICD-10: I73, I73.0] | Discontinued in Phase 2 | [1] | ||
| Company |
Kadmon Pharmaceuticals; Nano Terra
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022583) | |||
| REF 2 | Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.